ADMA Biologics shares plunge 24% after withdrawing financial guidance amid fraud allegations.

ADMA Biologics' stock dropped over 24% following the company's withdrawal of its long-term financial guidance due to changing market conditions. This move came after a report accused ADMA of inflating growth through questionable practices related to its product Asceniv. Legal firm Block & Leviton is investigating potential securities violations and encourages affected investors to contact them for possible recovery of losses. Investors who purchased ADMA shares and suffered losses may be eligible for legal action as the investigation continues.